Maternal antibiotic use is associated with childhood asthma, but the association is not specific to antibiotic use during pregnancy.
Introduction
Asthma is the most common chronic disease of childhood 1 , affecting over 10% of children worldwide 2 . In the United States, the total cost of asthma to society is estimated at $56 billion per year 3 . Similarly, in Canada asthma is a leading cause of healthcare utilization, work absenteeism, lost productivity and diminished quality of life 4 . Given this large clinical and economic burden, and because there is no cure for asthma, it is important to identify modifiable risk factors to inform asthma prevention strategies.
The US Center for Disease Control reports that antibiotics are prescribed at 12.6% of all ambulatory care visits, and 30% of these prescriptions may be unnecessary 5 . Across different settings, between 20-40% of women are prescribed antibiotics during pregnancy [6] [7] [8] [9] , accounting for nearly 80% of all drugs used by pregnant women 6 . Prenatal antibiotic use may result in fetal exposure as at least 11 types of broad-spectrum antibiotics cross the placenta, including penicillins, tetracyclines, and lincosamides 10 . Mounting evidence shows that early-life exposure to antibiotics can have long-term health effects by perturbing the gut microbiota and disrupting immune system development [11] [12] [13] . However, relatively few of these studies have addressed antibiotic use during pregnancy, which could modify the maternal microbiota before its transmission to the fetus or infant during gestation, delivery, postnatal contact, and lactation 14, 15 .
Several longitudinal studies [16] [17] [18] and meta-analyses [19] [20] [21] indicate that antibiotic exposure during infancy is a risk factor for asthma (pooled OR 1.52, 95%CI 1.30 -1.77; 20 studies; 685,550 participants) 20 , although some reports suggest confounding by indication or reverse causation 21, 22 . Fewer studies have evaluated prenatal antibiotic exposure 23 , with some [24] [25] [26] [27] [28] reporting increased asthma risk and others finding no association 29, 30 . These previous studies have variably reported associations by antibiotic type 26, 27, 29 , dose 26, 28 , and trimester of exposure [27] [28] [29] , but no single study has addressed all of these factors, and only a few have accounted for postnatal antibiotic use 25, 31 . A recent study by Stokholm et al. 30 found that maternal antibiotic use before, during, and after pregnancy was similarly associated with asthma risk among offspring, suggesting that maternal propensity for infection (rather than antibiotic use per se) may be responsible of this association.
Using administrative health data capturing all children born in Manitoba, Canada from 1996-2012, we undertook a population-based study examining the association of maternal antibiotic use and childhood asthma. We classified antibiotics by type, number of courses, and timing of exposure, and controlled for postnatal antibiotic use. We also performed a sensitivity analysis to determine whether associations were specific to maternal antibiotic use during pregnancy.
Patients and Methods

Study design, population and data sources
We conducted a retrospective cohort study of mother-infant dyads in Manitoba, Canada. Using 
Primary outcome: child asthma
Asthma was defined as meeting any of the following criteria after 5 years of age: 1) any hospitalization for asthma; or 2) ≥2 physician diagnoses of asthma, at least 3 months apart and within a 1 year period; or 3) ≥2 prescriptions for asthma medications within a 1 year period. The age requirement was applied because five years is the minimum age for confirming asthma diagnosis by lung function testing and misdiagnosis is common before this age 35 . We used the actual index date (the date when the child first met any of the above criteria, which could be prior to age 5) to capture incident cases for survival analysis. This definition was based on the validated definition applied by Kozyrskyj et al. using the same administrative database 17 . We modified this definition to increase specificity by requiring repeated physician diagnoses to be at least 3 months apart.
Potential confounders
The following potential confounders were documented from administrative health records: infant sex, residence location (urban or rural), length of gestation, number of siblings, and maternal asthma (defined using the algorithm described above). Postnatal antibiotic exposure in the first year of life (any or none) was determined from infant prescription records.
Statistical analysis
We conducted a time-to-event analysis, measuring time to event from a child's birthdate to the earliest of the following dates: date the child first met the asthma diagnosis definition, death, loss to follow up, or the end of the study period (March 31, 2015) . Associations between prenatal antibiotic exposure and childhood asthma were estimated using Cox regression models and reported as crude and adjusted hazard ratios (HR, aHR) and 95% confidence intervals (CI), with adjustment for known asthma risk factors (e.g. male sex, maternal asthma) and confounders that either changed the crude estimates appreciably or were considered confounders a priori (e.g.
antibiotic use in infancy, socioeconomic status). We conducted sensitivity analyses examining maternal antibiotic use during the 9-month window before and after pregnancy (defined based on the infant's birth date and gestational age). We modeled interaction terms to test for effect modification by infant sex, method of birth and newborn feeding method, and tested for the significance of including interaction terms using likelihood ratio tests.
Results
Our study population consisted of 213,661 mother-child dyads with a median follow-up time of 9.3 years from birth. The mean maternal age was 27.6 ± 5.9 years and 6.0% of mothers had asthma ( Table 1 pregnancy. Beta-lactam penicillins were the most commonly prescribed type of antibiotic (24.6%), with fewer mothers receiving other beta-lactams (6.1%); macrolides, lincosamides, or streptogramins (7.1%); tetracyclines, aminoglycosides, or quinolones (7.5%); and sulphonamides or trimethoprim (2.6%).
Mothers with asthma were more likely to use antibiotics during pregnancy (56.2% vs. 35.5%
among mothers with vs. without asthma, p<0.0001), and their children had a higher rate of asthma (21.0 vs. 9.6 cases per 1000 person-years, p <0.0001) ( Table 3) . Preterm birth was also positively associated with increased maternal antibiotic use and child asthma. In contrast, rural residence location and higher birth order were both positively associated with maternal antibiotic use but inversely associated with child asthma. These potential confounders were included in multivariable models to determine the independent association of maternal antibiotic use and child asthma (Table 4) .
Children born to mothers receiving antibiotics during pregnancy had significantly higher rates of asthma (11.9 per 1000 person-years, 95%CI 11.6-12.1) compared to their unexposed counterparts (9.2, 95%CI 9.0-9.4) ( (Table 5 ).
Discussion
In this population-based study, prenatal antibiotic exposure was associated with a 23% increased risk of asthma, independent of postnatal antibiotic exposure and several established asthma risk factors. There was an apparent dose-response with repeated prenatal exposures; however, similar associations were observed for maternal antibiotic use before and after pregnancy. These results do not firmly support nor refute a directly causal pregnancy-specific relationship between maternal antibiotic use and childhood asthma; however, they contribute to the growing body of evidence linking early-life antibiotic exposure and asthma risk, and raise important questions for further research. It is conceivable that maternal antibiotic use before, during and after pregnancy could impact infant microbiota and subsequent immune development. Pre-gestational antibiotic use may have long-term effects on the maternal microbiota that persist during pregnancy, and post-partum antibiotics could influence the transmission of maternal skin and breast milk microbiota to the infant 37 . Consistent with Mulder et al. 27 , our finding that different types of antibiotics are differentially associated with child asthma lends support to this hypothesis, since different antibiotics will differentially impact maternal microbiota and their transmission to the infant. antibiotic use is a marker of genetic susceptibility to infections, which is inherited by offspring and imparts a predisposition for asthma 30 . Third, as Weiss et al. suggested, a maternal deficiency in vitamin D or other immunomodulatory nutrient could explain the increased risk of infection in mothers and increased risk of asthma in offspring 38 . Finally, since maternal and child medication usage are strongly associated 39 , it is possible that maternal antibiotic use is a surrogate for infant antibiotic use, which is known to influence asthma development 17, 18 . While we could not address environmental exposures, genetics, or nutritional hypotheses in our administrative database study, our findings do not support the final explanation since our results were unchanged following adjustment for infant antibiotic use.
Notably, the dose-response observed by Stokholm et al 30 and others 26, 28, 31 , and replicated in our study, suggests that antibiotics or some related underlying factor (whether genetic, nutritional, or environmental) may be causally related to asthma development in offspring. While this pattern could also indicate dose-response in a confounder, research is warranted to pursue these hypotheses in other settings where causal mechanisms can be explored and tested, such as clinical cohorts and animal models. It must also be acknowledged that, while the overuse of antibiotics can promote antimicrobial resistance and microbiome dysbiosis, untreated infections can also be harmful, especially to a developing fetus. For example, urinary tract infections during pregnancy are associated with intrauterine growth restriction, preterm labor, and miscarriage 40, 41 .
Keeping this risk-benefit balance in mind, it is important to study and clarify the potentially unintended consequences of prenatal antibiotic exposure.
Another approach to address confounding in prenatal exposure studies is to evaluate fathers' exposures as a negative control. Mulder et al. reported that maternal (but not paternal) antibiotic use during pregnancy was associated with child asthma at age 5, supporting a causal effect from in utero exposure 27 . In contrast, Ortqvist et al. showed that both maternal and paternal antibiotic use during pregnancy were associated with child asthma before 2.5 years 36 , suggesting confounding by shared familial factors. Notably, however, the maternal association was stronger and persistent throughout childhood, whereas paternal exposure was not associated with child asthma after 2.5 years. Thus, while we could not address paternal exposure in our study, this approach warrants further investigation.
Strengths of this study include the large unselected population, capturing virtually all children born in the province of Manitoba over an 18-year period, and the use of administrative healthcare data to objectively document asthma diagnoses, hospitalizations, and antibiotic exposures. Using healthcare records eliminates recall bias, minimizes loss to follow-up, and provides key details that are not accurately captured by self-report, including the specific antibiotic type, dose, and timing of exposure. Unlike most previous studies, we mutually adjusted our analyses for prenatal and postnatal antibiotic exposure during the first year of life -an important adjustment since maternal and infant healthcare utilization tend to be correlated 39 but could be independently associated with child asthma development. We also performed sensitivity analyses for maternal antibiotic use before and after pregnancy, although sibling controls and paternal exposures were not examined. Finally, our results confirm previous research 19 identifying maternal asthma, male sex, urban residence, premature birth, and lower birth order as significant risk factors for asthma.
A limitation of our study is the lack of information about the indication for antibiotic treatment.
In addition, exposure misclassification is possible since we cannot confirm patient compliance with filled prescriptions, and our database does not capture antibiotics administered in hospital.
Thus, we could not account for intrapartum antibiotic prophylaxis for Group B Streptococcus, which affects over 20% of deliveries in Manitoba 42 and has been shown to influence infant gut microbiota development 43 . We also could not account for indirect exposure to antibiotics in food or the environment 44 . Outcome misclassification is also possible since asthma is commonly misdiagnosed in young children; however, we evaluated multiple disease definitions and required evidence of serious (hospitalization) or persistent (multiple diagnoses or prescriptions) disease after 5 years of age to maximize specificity. Finally, confounding bias is possible since we could not account for potential confounders that are not captured in administrative databases, such as maternal and child nutrition, education, smoking, and environmental exposures including pets, tobacco smoke, mould and daycare attendance.
Conclusions
In this province-wide study, we observed a dose-dependent association between maternal antibiotic use and asthma risk in offspring; however, this association was not specific to antibiotic use during pregnancy. Further research is needed to better understand the nature of this association and address intrapartum antibiotic exposure. While our current results do not firmly support nor refute a directly causal pregnancy-specific relationship between maternal antibiotic use and childhood asthma, it remains important to use antibiotics judiciously. To isolate the effect of antibiotic use during each of the three exposure periods of interest, mothers were excluded if they used antibiotics during more than one exposure period. 100.0% Shading is proportional to the proportion of maternal antibiotic use (0% = white, 100% = black).
